On Astellas Pharma’s mission to develop new cell therapies in cancers and other diseases, not all candidates are destined to ...

A phase 3 trial reveals that combining brentuximab vedotin with lenalidomide and rituximab improves survival in relapsed ...

Research shows routine follow-up misses most relapses in lymphoma patients in remission, highlighting the need for improved ...

Australian immuno-oncology company Imugene has dosed the first Australian subject in a Phase Ib trial of its allogeneic CAR T ...

BOULDER, Colo., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Foresight Diagnostics (Foresight), a leader in ultra-sensitive minimal residual disease (MRD) detection technology, today provided its strategic ...

Dr John Leonard shares key updates on DLBCL at ASH 2024, including long-term POLARIX trial data, ctDNA insights, and real-world results for polatuzumab, liso-cel, and bispecifics after CAR-T failure.

In recent years, the FDA has amped up its supervision of accelerated approvals, including by requiring that confirmatory ...

Tevimbra is under clinical development by BeiGene and currently in Phase II for Marginal Zone B-cell Lymphoma.

XYF-19 is under clinical development by Xi'An Yufan Biotechnology and currently in Phase I for Diffuse Large B-Cell Lymphoma.

Nkarta focuses on autoimmune diseases, with $402.5M in cash. Read why NKTX stock, currently undervalued, offers multiple ...

As we start the New Year, it’s time to schedule your annual wellness visit. This important appointment is to talk about any ...

Professor Michel Sadelain, of Canadian origins, was announced the 2025 laureate for King Faisal Prize in Medicine for his groundbreaking contributions to Chimeric Antigen Receptor (CAR) T-cell therapy ...